HUADONG MEDICINE(SZ:000963) Bank of China Securities·2025-08-25 00:02Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance in the next 6-12 months [1][5]. Core Insights - The company reported a total revenue of RMB 21.675 billion for the first half of 2025, representing a year-on-year growth of 3.39%. The net profit attributable to shareholders was RMB 1.815 billion, up 7.01% year-on-year, while the net profit excluding non-recurring items was RMB 1.762 billion, reflecting an 8.40% increase [3][5]. - The company plans to distribute a cash dividend of RMB 3.50 per 10 shares (tax included) and will not issue bonus shares [3]. - The company is experiencing steady growth in its business, with innovative products gradually entering the harvest phase, which supports a positive long-term development outlook [3][5]. Financial Projections - The forecast for net profit attributable to shareholders for 2025-2027 is RMB 4.162 billion, RMB 4.782 billion, and RMB 5.404 billion, respectively. The corresponding earnings per share (EPS) are projected to be RMB 2.37, RMB 2.73, and RMB 3.08 [5][7]. - The current price-to-earnings (P/E) ratios for 2025-2027 are 19.3, 16.8, and 14.8 times, respectively, indicating a favorable valuation [5][7]. Business Performance - The industrial segment of the company continues to show good growth, with a revenue of RMB 10.939 billion in the second quarter of 2025, marking a year-on-year increase of 3.65% [8]. - The innovative products have generated sales and agency service revenue of RMB 1.084 billion, with a year-on-year growth rate of 59% [8]. - The company has established a strong commercial network, ensuring the continued growth of its innovative products [8].